Robert Burns
Stock Analyst at HC Wainwright & Co.
(1.27)
# 3,521
Out of 4,893 analysts
475
Total ratings
32.69%
Success rate
-13.14%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Burns
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COGT Cogent Biosciences | Maintains: Buy | $12 → $22 | $10.85 | +102.76% | 12 | Jul 8, 2025 | |
| REPL Replimune Group | Reiterates: Buy | $22 | $10.77 | +104.27% | 17 | Jul 3, 2025 | |
| ZYME Zymeworks | Reiterates: Neutral | $13 | $13.67 | -4.87% | 21 | Jul 3, 2025 | |
| TLX Telix Pharmaceuticals | Initiates: Buy | $23 | $16.10 | +42.86% | 1 | Jul 3, 2025 | |
| ELVN Enliven Therapeutics | Maintains: Buy | $40 → $48 | $22.75 | +110.99% | 5 | Jul 2, 2025 | |
| EXEL Exelixis | Maintains: Buy | $47 → $53 | $45.17 | +17.33% | 9 | Jun 30, 2025 | |
| BNTX BioNTech SE | Reiterates: Buy | $138 | $113.92 | +21.14% | 43 | Jun 25, 2025 | |
| IMMX Immix Biopharma | Reiterates: Buy | $7 | $2.70 | +159.74% | 8 | Jun 4, 2025 | |
| YMAB Y-mAbs Therapeutics | Maintains: Buy | $12 → $11 | $4.53 | +142.83% | 21 | May 19, 2025 | |
| BCAX Bicara Therapeutics | Maintains: Buy | $44 → $41 | $9.92 | +313.31% | 4 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $2.52 | +376.19% | 3 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $39 → $40 | $22.00 | +81.82% | 9 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $73 → $72 | $38.50 | +87.01% | 20 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $22 | $11.45 | +92.14% | 24 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $18 | $4.16 | +332.69% | 2 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.91 | +449.75% | 16 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $3 | $1.74 | +72.41% | 14 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $6.11 | +112.77% | 12 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $36 | $12.67 | +184.14% | 15 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $8.37 | +19.55% | 7 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $3.30 | +142.42% | 21 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $4.11 | +143.31% | 3 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $2 | $1.58 | +26.58% | 21 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $1.27 | +293.70% | 11 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $8 | $1.26 | +534.92% | 17 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $12 | $2.74 | +337.96% | 13 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $34 | $2.55 | +1,233.33% | 3 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $10 | $2.31 | +332.90% | 14 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $5 | $1.56 | +220.51% | 18 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $16 | $3.73 | +328.95% | 21 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.60 | - | 4 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $9.54 | - | 13 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $12 → $11 | $1.36 | +708.82% | 13 | Sep 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $500 → $200 | $5.70 | +3,408.77% | 5 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $110 → $20 | $1.00 | +1,904.01% | 2 | Mar 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.99 | - | 6 | Jan 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $150 | $2.29 | +6,450.22% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $22 | $1.38 | +1,494.20% | 4 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $115 → $7 | $1.16 | +503.45% | 7 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $11 | $2.60 | +323.08% | 1 | Dec 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $250 → $225 | $0.06 | +376,784.42% | 7 | Nov 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $25 | $3.55 | +604.21% | 1 | Jun 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $13 | $2.48 | +424.19% | 1 | Jan 7, 2021 |
Cogent Biosciences
Jul 8, 2025
Maintains: Buy
Price Target: $12 → $22
Current: $10.85
Upside: +102.76%
Replimune Group
Jul 3, 2025
Reiterates: Buy
Price Target: $22
Current: $10.77
Upside: +104.27%
Zymeworks
Jul 3, 2025
Reiterates: Neutral
Price Target: $13
Current: $13.67
Upside: -4.87%
Telix Pharmaceuticals
Jul 3, 2025
Initiates: Buy
Price Target: $23
Current: $16.10
Upside: +42.86%
Enliven Therapeutics
Jul 2, 2025
Maintains: Buy
Price Target: $40 → $48
Current: $22.75
Upside: +110.99%
Exelixis
Jun 30, 2025
Maintains: Buy
Price Target: $47 → $53
Current: $45.17
Upside: +17.33%
BioNTech SE
Jun 25, 2025
Reiterates: Buy
Price Target: $138
Current: $113.92
Upside: +21.14%
Immix Biopharma
Jun 4, 2025
Reiterates: Buy
Price Target: $7
Current: $2.70
Upside: +159.74%
Y-mAbs Therapeutics
May 19, 2025
Maintains: Buy
Price Target: $12 → $11
Current: $4.53
Upside: +142.83%
Bicara Therapeutics
May 16, 2025
Maintains: Buy
Price Target: $44 → $41
Current: $9.92
Upside: +313.31%
May 16, 2025
Reiterates: Buy
Price Target: $12
Current: $2.52
Upside: +376.19%
May 14, 2025
Maintains: Buy
Price Target: $39 → $40
Current: $22.00
Upside: +81.82%
May 14, 2025
Maintains: Buy
Price Target: $73 → $72
Current: $38.50
Upside: +87.01%
May 9, 2025
Maintains: Buy
Price Target: $21 → $22
Current: $11.45
Upside: +92.14%
May 9, 2025
Maintains: Buy
Price Target: $17 → $18
Current: $4.16
Upside: +332.69%
May 5, 2025
Reiterates: Buy
Price Target: $5
Current: $0.91
Upside: +449.75%
Apr 28, 2025
Maintains: Buy
Price Target: $9 → $3
Current: $1.74
Upside: +72.41%
Apr 14, 2025
Reiterates: Buy
Price Target: $13
Current: $6.11
Upside: +112.77%
Apr 2, 2025
Reiterates: Buy
Price Target: $36
Current: $12.67
Upside: +184.14%
Apr 2, 2025
Reiterates: Buy
Price Target: $10
Current: $8.37
Upside: +19.55%
Mar 31, 2025
Reiterates: Buy
Price Target: $8
Current: $3.30
Upside: +142.42%
Mar 31, 2025
Reiterates: Buy
Price Target: $10
Current: $4.11
Upside: +143.31%
Mar 25, 2025
Maintains: Neutral
Price Target: $4 → $2
Current: $1.58
Upside: +26.58%
Mar 20, 2025
Reiterates: Buy
Price Target: $5
Current: $1.27
Upside: +293.70%
Mar 19, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $1.26
Upside: +534.92%
Mar 18, 2025
Maintains: Buy
Price Target: $11 → $12
Current: $2.74
Upside: +337.96%
Mar 18, 2025
Maintains: Buy
Price Target: $40 → $34
Current: $2.55
Upside: +1,233.33%
Mar 10, 2025
Maintains: Buy
Price Target: $11 → $10
Current: $2.31
Upside: +332.90%
Mar 7, 2025
Maintains: Buy
Price Target: $10 → $5
Current: $1.56
Upside: +220.51%
Mar 7, 2025
Reiterates: Buy
Price Target: $16
Current: $3.73
Upside: +328.95%
Jan 30, 2025
Downgrades: Neutral
Price Target: n/a
Current: $4.60
Upside: -
Jan 28, 2025
Reiterates: Neutral
Price Target: n/a
Current: $9.54
Upside: -
Sep 5, 2024
Maintains: Neutral
Price Target: $12 → $11
Current: $1.36
Upside: +708.82%
May 8, 2024
Maintains: Buy
Price Target: $500 → $200
Current: $5.70
Upside: +3,408.77%
Mar 21, 2024
Maintains: Buy
Price Target: $110 → $20
Current: $1.00
Upside: +1,904.01%
Jan 8, 2024
Downgrades: Neutral
Price Target: n/a
Current: $5.99
Upside: -
Aug 8, 2023
Reiterates: Buy
Price Target: $150
Current: $2.29
Upside: +6,450.22%
Mar 17, 2023
Reiterates: Buy
Price Target: $22
Current: $1.38
Upside: +1,494.20%
Jan 24, 2023
Downgrades: Neutral
Price Target: $115 → $7
Current: $1.16
Upside: +503.45%
Dec 22, 2021
Maintains: Buy
Price Target: $12 → $11
Current: $2.60
Upside: +323.08%
Nov 24, 2021
Maintains: Buy
Price Target: $250 → $225
Current: $0.06
Upside: +376,784.42%
Jun 21, 2021
Assumes: Buy
Price Target: $25
Current: $3.55
Upside: +604.21%
Jan 7, 2021
Maintains: Buy
Price Target: $19 → $13
Current: $2.48
Upside: +424.19%